Targets › F8
22 programs from 20 companies in 31 trials: 15 Phase 3, 8 Phase 4, 7 Phase 1, 1 Phase 2; Hematology, Other; next expected readout Nov 2026.
Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa. (UniProt, P00451)
Open in Phaseline: the race on F8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Swedish Orphan Biovitrum | Efanesoctocog alfa Coagulation factor VIII exogenous protein | F8 | Phase 4 | Haemophilia A (Moderate or Severe); Hemophilia A | Nov 2026 |
| Octapharma | Simoctocog Alfa Coagulation factor VIII exogenous protein | F8 | Phase 4 | Severe Hemophilia A; Hemophilia A | Feb 2027 |
| University Hospital, Basel, Switzerland | Wilate 1:1 balanced mixture of von Willebrand Factor and Coagulation Factor VIII | F8, VWF | Phase 4 | Bleeding | Nov 2027 |
| Runhui WU | Octocog Alfa Coagulation factor VIII exogenous protein | F8 | Phase 4 | Hemophilia a with Inhibitor | Mar 2028 |
| Grifols Biologicals | Alphanate SD/HT Factor VIII/von Willebrand Factor (vWF) concentrate | F8, VWF | Phase 4 | Von Willebrand Disease | – |
| Gritgen Therapeutics | GS1191-0445 injection AAV8-delivered gene therapy expressing B-domain deleted human factor VIII (FVIII) | F8 | Phase 3 | Hemophilia A; Severe Hemophilia A | Nov 2026 |
| Bioverativ, a Sanofi company | Efanesoctocog Alfa (BIVV001) Coagulation factor VIII exogenous protein | F8 | Phase 3 | Hemophilia A | Jan 2027 |
| Hangzhou Gensciences Biopharmaceutical | FRSW107 Recombinant human coagulation Factor VIII-Fc fusion protein | F8 | Phase 3 | Severe Hemophilia A | Feb 2027 |
| Roche | NXT007 Factor VIII mimetic/extended half-life factor VIII replacement | F8 | Phase 3 | Hemophilia A | Sep 2027 |
| Unity Health Toronto | Wilate Von Willebrand Factor and Factor VIII concentrate | VWF, F8 | Phase 3 | Von Willebrand Diseases | Dec 2027 |
| Novo Nordisk | Denecimig (Mim8) Recombinant Factor VIII replacement | F8 | Phase 3 | Haemophilia A | Jun 2028 |
| Sinocelltech | Omfiloctocog Alfa (SCT800) Coagulation factor VIII exogenous protein | F8 | Phase 3 | Haemophilia A; Hemophilia A With Inhibitor | Dec 2028 |
| Pfizer | giroctocogene fitelparvovec AAV5 gene therapy delivering factor VIII | F8 | Phase 3 | Hemophilia A | Feb 2040 |
| CSL Behring | Lonoctocog Alfa Coagulation factor VIII exogenous protein | F8 | Phase 3 | Congenital Hemophilia A | – |
| Pfizer | PF-07055480 / Giroctocogene Fitelparvovec Recombinant AAV2/6 human Factor VIII gene therapy | F8 | Phase 3 | Hemophilia A | – |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | Recombinant human coagulation factor VIII for injection Recombinant human coagulation factor VIII (replacement therapy) | F8 | Phase 3 | Hemophilia A | – |
| Shanghai Xinzhi BioMed | BBM-H803 AAV vector expressing human factor VIII transgene | F8 | Phase 2 | Hemophilia A | May 2027 |
| ASC Therapeutics | ASC618 AAV vector encoding B-domain deleted codon-optimized human factor VIII | F8 | Phase 1 | Hemophilia A | Dec 2026 |
| Medical College of Wisconsin | Pleightlet(MUT6) Lentiviral vector encoding B-domain-deleted human coagulation factor VIII (BDDFVIII) for p | F8 | Phase 1 | Hemophilia A | Mar 2027 |
| University College, London | AAV2/8-HLP-FVIII-V3 AAV2/8-mediated gene transfer of coagulation factor VIII | F8 | Phase 1 | Hemophilia A | Jan 2029 |
| Roche | SPK-8011QQ (RO7878488) Gene therapy for Factor VIII deficiency | F8 | Phase 1 | Hemophilia A | Apr 2032 |
| Biocad | ANB-010 Adeno-associated viral vector carrying the FVIII gene | F8 | Phase 1 | Hemophilia A | Jun 2033 |
Hemophilia A (16) Severe Hemophilia A (4) Haemophilia A (3) Haemophilia A (Moderate or Severe) (2) Hemophilia A With Inhibitor (1) Von Willebrand Diseases (1) Hemophilia a with Inhibitor (1) Bleeding (1) Von Willebrand Disease (1) Congenital Hemophilia A (1)
small molecule (9), other (5), protein or peptide (5), mixed (1), antibody (1)
Pfizer (2) Roche (2) Swedish Orphan Biovitrum (1) Medical College of Wisconsin (1) Sinocelltech (1) Octapharma (1) University College, London (1) Unity Health Toronto (1) ASC Therapeutics (1) Bioverativ, a Sanofi company (1) Biocad (1) Hangzhou Gensciences Biopharmaceutical (1) Gritgen Therapeutics (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1) Runhui WU (1) Shanghai Xinzhi BioMed (1) University Hospital, Basel, Switzerland (1) Novo Nordisk (1) Grifols Biologicals (1) CSL Behring (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.